
Immunovant Inc (IMVT) Stock Forecast & Price Target
Immunovant Inc (IMVT) Analyst Ratings
Bulls say
Immunovant Inc is focused on developing IMVT-1402, an FcRn inhibitor aimed at reducing pathogenic IgG antibodies related to autoimmune diseases, highlighting its potential in addressing conditions like Graves' disease (GD). The company's clinical data indicates a sustained reduction in TRAb levels during the off-treatment period and an impressive responder rate of 81%, comparably robust to the active treatment phase. These findings underscore the durability of effect and disease-modifying potential of FcRn blockers, fostering a positive outlook for Immunovant's stock.
Bears say
Immunovant Inc's outlook remains negative due to the ongoing risks associated with persistently high TRAbs levels, which have been linked to increased rates of relapse in patients. The potential complications arising from TRAbs-mediated TSHR activation, including severe inflammation and the risk of optic nerve compression, underline significant clinical challenges that may impede the company's development efforts. Additionally, the focus on a single operating segment raises concerns about the company's ability to diversify its risk profile and effectively manage its reliance on the success of its product candidates.
This aggregate rating is based on analysts' research of Immunovant Inc and is not a guaranteed prediction by Public.com or investment advice.
Immunovant Inc (IMVT) Analyst Forecast & Price Prediction
Start investing in Immunovant Inc (IMVT)
Order type
Buy in
Order amount
Est. shares
0 shares